An Observational Prospective Registry of Atrial Fibrillatio

Not Applicable

Recruiting

• Conditions: Atrial Fibrillation; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12621001506886
• Lead Sponsor: The University of Adelaide

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-11-04
• Last Update Posted: 18 September 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1500

Inclusion Criteria

•Clinical diagnosis of AF
•Capacity to provide informed consent

Exclusion Criteria

•Less than12 months of life expectancy
•Severe valvular disease i.e. mitral or aortic valve disease
•Cardiac surgery in the last three months, or expected during first six months of study period
•A recent history (< 1 year) of current malignancy, advanced heart failure (NYHA class IV), or end stage COAD or Interstitial lung disease other severe life-threatening comorbidities
•Parkinson’s disease
•Alzheimers disease
•Aphasia
•Severe psychiatric disorders e.g. schizophrenia, schizoaffective disorder or bipolar disorder
•An inability to provide informed consent

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The composite outcomes of cognitive decline and stroke.<br>The outcomes will be assessed via clinical visit and data-linkage to medical records.[ The outcome will be assessed every 12 months (months 12, 24, 36, 28, and 60) up to 5 years follow-up after enrolment. ];The outcomes of mortality, assessed via clinical visit and data-linkage to medical records.[ The outcome will be assessed every 12 months (months 12, 24, 36, 28, and 60) up to 5 years follow-up after enrolment. ];The composite of outcomes of heart failure and unplanned hospitalizations.<br>The composite of outcomes of heart failure and unplanned hospitalizations will assessed via clinical visit and data-linkage to medical records.[ The outcome will be assessed every 12 months (months 12, 24, 36, 28, and 60) up to 5 years follow-up after enrolment. ]

Secondary Outcome Measures

Name	Time	Method
incidence of tachycardia induced cardiomyopathy, assessed by data-linkage to medical records<br>[ The outcome will be assessed every 12 months (months 12, 24, 36, 28, and 60) up to 5 years follow-up after enrolment. ]